Neuren Pharmaceuticals Limited ( ASX:NEU ) came out with its interim results last week, and we wanted to see how the...
With its stock down 28% over the past three months, it is easy to disregard Neuren Pharmaceuticals (ASX:NEU). However...
The Australian market has shown robust growth, climbing 3.0% in the past week and achieving a 10% increase over the last twelve months, with earnings projected to grow by 14% per annum. In this context, identifying undervalued small-cap stocks can offer potential opportunities for investors looking to capitalize on companies with promising prospects yet to be fully recognized by the broader market.